The Liver Meeting 2024 - Debrief Sessions - Spanish-MASLD Debrief Session

Video Transcription

Video Summary

Dr. Alina Allen, a hepatologist and director at the Mayo Clinic, presented the Maslil debrief at ASLD 2024. Key themes included significant scientific advancements in omics, pediatric Maslil data, and drug therapies. The presentation highlighted various studies, including genomic analysis on drugs like resmeterome and terzapatide showing that genetic markers did not significantly impact NASH and fibrosis treatment outcomes. In pediatrics, distinct metabolotypes were identified, suggesting varied treatment pathways. A study on GLP-1 receptor agonists showed promise in improving ALT levels in pediatric Maslil, though it did not affect weight outcomes. Another study in adults supported the favorable impacts of GLP-1 on disease progression and mortality. Furthermore, phase 2 and 3 clinical trials for new drugs, including FGF21 and THR beta analogs, showed promising fibrosis improvement. Overall, the research suggests potential for more effective and targeted treatments for Maslil in both adults and children.

Keywords

Maslil

omics

genomic analysis

GLP-1 receptor agonists

fibrosis treatment

pediatric metabolotypes